Search Results

You are looking at 41 - 50 of 135 items for :

  • "febrile neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Jeffrey Crawford and George M. Rodgers

Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays

Full access

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman

descriptive review . Nat Clin Pract Oncol 2007 ; 4 : 643 – 656 . 29. Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 30

Full access

Harold J. Burstein

. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no

Full access

Michael Kleinberg

amikacin as empiric therapy for febrile neutropenia . Clin Infect Dis 2001 ; 33 : 1295 – 1301 . 26 Gomez L Garau J Estrada C . Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of

Full access

Marc Fishman, William Shimp, James Krook, Akhil Kumar, and William J.M. Hrushesky

alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We

Full access

Bradford R. Hirsch and Gary H. Lyman

benefit. As an example, the demonstration of efficacy for G-CSF agents may include absolute neutrophil counts, CD34 + cell counts, the duration of severe neutropenia (neutrophils <500 cells/μL), and rates of febrile neutropenia. However, surrogates may be

Full access

Komal Jhaveri and Francisco J. Esteva

DLTs of grade 3 fatigue and grade 4 febrile neutropenia. 25 Based on the DLT noted in this trial and other phase II data available that showed no difference in toxicity or efficacy between the 2 doses of pertuzumab, the recommended phase II doses were

Full access

Bradford R. Hirsch and Gary H. Lyman

, to overcome any hesitancy among clinicians about the efficacy and safety of biosimilars, the new agent must have adequate clinical data showing comparability to the established agents in reducing the risk of severe febrile neutropenia. In anticipation

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

Kuderer N Greene J . The economics of febrile neutropenia: implications for the use of colony-stimulating factors . Eur J Cancer 1998 ; 34 : 1857 – 1864 . 17 Blay JY Chauvin F Le Cesne A . Early lymphopenia after cytotoxic

Full access

Andrew D. Zelenetz and Pamela S. Becker

indications as filgrastim: to treat patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia (FN); patients with acute myeloid leukemia receiving induction or